Previous 10 | Next 10 |
SilverBow Resorces Inc. (SBOW) is expected to report $2.36 for Q4 2023 FAT Brands Inc. Class B Common Stock (FATBB) is expected to report for quarter end 2023-12-31 Ecovyst Inc. (ECVT) is expected to report $0.2 for Q4 2023 MYR Group Inc. (MYRG) is expected to report $1.41 for Q4 2023...
CORAL GABLES, Fla., Feb. 27, 2024 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst") (Nasdaq: CPRX), a commercial-stage, patient-centric biopharmaceutical company focused on in-licensing, developing, and commercializing novel high-quality medicines for patients living with rare and d...
CORAL GABLES, Fla., Feb. 21, 2024 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (“Catalyst” or “Company”) (Nasdaq: CPRX), a commercial-stage, patient-centric biopharmaceutical company focused on in-licensing, developing, and commercializing novel high-quality...
CORAL GABLES, Fla., Feb. 14, 2024 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (“Catalyst”) (Nasdaq: CPRX), a commercial-stage, patient-centric biopharmaceutical company focused on in-licensing, developing, and commercializing novel high-quality medicines for patients liv...
2024-02-08 10:32:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-01-25 08:00:00 ET Summary Alex Carchidi calls the biotech sector highly risky and speculative, and says diversification is key for investors. Funding is currently difficult to obtain in the biotech industry, but a turnaround is expected. Competitive stories in gene editin...
2024-01-22 19:45:34 ET Summary Catalyst Pharmaceuticals is a biopharmaceutical company specializing in treatments for rare neurological and epileptic disorders. The company's main products are Firdapse and Fycompa, which make up the majority of its revenue. The launch of Agamr...
2024-01-18 04:54:59 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips The International Monetary Fund believes that most of the impact from tighter money policies has already affected the U.S. economy, with the rest expected this year. Despite worries about a rec...
2024-01-17 19:50:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-01-17 14:13:32 ET Summary Catalyst Pharmaceuticals, Inc. has one approved product and another about to be launched, but its market cap is low at $1.7bn. The company is facing a major patent challenge and has high expenses with no major data catalysts or pipeline molecules. ...
News, Short Squeeze, Breakout and More Instantly...
Catalyst Pharmaceuticals Inc. Company Name:
CPRX Stock Symbol:
NASDAQ Market:
Catalyst Pharmaceuticals Inc. Website:
2024-06-20 17:18:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-06-03 11:30:04 ET H.C. Wainwright analyst issues UNDERPERFORM recommendation for CPRX on June 3, 2024 09:00AM ET. The previous analyst recommendation was Underperform. CPRX was trading at $16.38 at issue of the analyst recommendation. The overall analyst consensus :...
2024-06-03 10:15:02 ET Oppenheimer analyst issues BUY recommendation for CPRX on June 3, 2024 09:00AM ET. The previous analyst recommendation was Buy. CPRX was trading at $16.38 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current anal...